Innoviva (INVA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.03
- Estimate
- $0.34
- Surprise
- -402.9%
- Revenue (period 2026-09-30)
- $106.1M
- Score today
- 6.5/10
Revenue source: xbrl.
How the report landed
Innoviva (INVA) reported a wider loss than forecast — adjusted EPS of -$1.03 against the $0.34 estimate (a 402.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates INVA Buy (Wait) at 6.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -402.9% surprise compares with a -92.9% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Negative momentum
- Momentum 1.6 < 4.5 minimum
- Momentum score 1.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.41
- Entry target
- $18.69
- Price target
- $30.45
- Stop
- $17.47
- Upside to target
- +56.9%
- Reward-to-risk
- 9.0:1
At 8.2× trailing and 8.7× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
INVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.39B
- P/E (fwd)
- 8.7
- P/E (ttm)
- 8.2
- 52-week range
- $18.85–$25.15
- Off 52-week high
- 22.8%
- RSI (14)
- 33
- Volume vs avg
- 0.61×
- Score today
- 6.5/10